Literature DB >> 25363092

Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma.

Yi-Sheng Tai1, Chung-Hsin Chen, Chao-Yuan Huang, Huai-Chin Tai, Sho-Mon Wang, Yeong-Shiau Pu.   

Abstract

BACKGROUND: The association of diabetes mellitus and bladder cancer recurrence following radical nephroureterectomies (RNUs) in patients with upper urinary tract urothelial carcinoma (UTUC) was investigated.
METHODS: Between January 1996 and March 2009, 538 patients with UTUC who received RNU and had no previous bladder cancer histories were enrolled. The clinicopathological characteristics were obtained and used for the analysis of metachronous bladder recurrence by using Cox proportional hazard model.
RESULTS: The diabetic patients (N = 104, 19.3%) were elderly (72 vs 67 years, p < 0.001) and had more hypertension (56.7 vs 34.5%, p < 0.001) as compared with non-diabetic patients. There was no significant difference in the rest of clinicopathological characteristics between patient groups. During the median follow-up duration of 51 months, bladder recurrences were discovered in 47.1 and 33.1% of diabetic and non-diabetic patients with UTUC, respectively. Poorly controlled diabetic patients (HbA1c  ≥ 7.0%) exhibited a shorter duration of bladder cancer recurrence-free survival as compared with those with good glycemic controlled diabetes mellitus and without diabetes mellitus (log-rank test, p < 0.001 and <0.001, respectively). In the multivariate analysis, male gender [hazard ratio (HR) = 1.67, p = 0.017], ureteral tumour (HR = 1.61, p = 0.020), end-stage renal disease (HR = 2.09, p = 0.030) and diabetes mellitus with poor glycemic control (HR = 2.10, p < 0.018) independently predicted bladder recurrence after RNU.
CONCLUSIONS: Diabetes mellitus with poor glycemic control (HbA1c  ≥ 7.0%) increases the risk of subsequent bladder cancer recurrence. These results underscore the need for intensive glycemic control and close follow-up for diabetic patients.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  HbA1c; bladder cancer; diabetes mellitus; upper urinary tract urothelial carcinoma

Mesh:

Year:  2014        PMID: 25363092     DOI: 10.1002/dmrr.2614

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  16 in total

Review 1.  Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review.

Authors:  Aurélie Mbeutcha; Morgan Rouprêt; Ashish M Kamat; Pierre I Karakiewicz; Nathan Lawrentschuk; Giacomo Novara; Jay D Raman; Christian Seitz; Evanguelos Xylinas; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-04-21       Impact factor: 4.226

2.  The prognostic significance of preoperatively assessed AST/ALT (De Ritis) ratio on survival in patients underwent radical cystectomy.

Authors:  Sacit Nuri Gorgel; Osman Kose; Esra Meltem Koc; Erhan Ates; Yigit Akin; Yuksel Yilmaz
Journal:  Int Urol Nephrol       Date:  2017-07-01       Impact factor: 2.370

3.  Duration of diabetes mellitus and risk of kidney and bladder cancer: a longitudinal nationwide cohort study.

Authors:  Young Hyo Choi; Yong-Moon Park; Kyung Jae Hur; U-Syn Ha; Sung-Hoo Hong; Ji Youl Lee; Sae Woong Kim; Kyungdo Han; Seung Hyun Ko; Yong Hyun Park
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

Review 4.  Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature.

Authors:  Aurélie Mbeutcha; Romain Mathieu; Morgan Rouprêt; Kilian M Gust; Alberto Briganti; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Transl Androl Urol       Date:  2016-10

5.  Pretreatment glycemic control status is an independent prognostic factor for cervical cancer patients receiving neoadjuvant chemotherapy for locally advanced disease.

Authors:  Jing Li; Ni-Ya Ning; Qun-Xian Rao; Rong Chen; Li-Juan Wang; Zhong-Qiu Lin
Journal:  BMC Cancer       Date:  2017-08-03       Impact factor: 4.430

6.  The association between metabolic syndrome and bladder cancer susceptibility and prognosis: an updated comprehensive evidence synthesis of 95 observational studies involving 97,795,299 subjects.

Authors:  Xiao-Fan Peng; Xiang-Yu Meng; Cheng Wei; Zhen-Hua Xing; Jia-Bin Huang; Zhen-Fei Fang; Xin-Qun Hu; Qi-Ming Liu; Zhao-Wei Zhu; Sheng-Hua Zhou
Journal:  Cancer Manag Res       Date:  2018-11-26       Impact factor: 3.989

7.  Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes Mellitus.

Authors:  Ji Hoon Ahn; Seung Il Jung; Sang Un Yim; Sun Woo Kim; Eu Chang Hwang; Dong Deuk Kwon
Journal:  J Korean Med Sci       Date:  2016-09       Impact factor: 2.153

8.  Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma.

Authors:  Chung-Hsin Chen; Kathleen G Dickman; Chao-Yuan Huang; Chia-Tung Shun; Huai-Ching Tai; Kuo-How Huang; Shuo-Meng Wang; Yuan-Ju Lee; Arthur P Grollman; Yeong-Shiau Pu
Journal:  Oncotarget       Date:  2016-07-19

9.  Effect of diabetes mellitus and glycemic control on the prognosis of non-muscle invasive bladder cancer: a retrospective study.

Authors:  Wei-Lun Huang; Kuo-How Huang; Chao-Yuan Huang; Yeong-Shiau Pu; Hong-Chiang Chang; Po-Ming Chow
Journal:  BMC Urol       Date:  2020-08-05       Impact factor: 2.264

Review 10.  Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis.

Authors:  Jiao Hu; Jin-Bo Chen; Yu Cui; Ye-Wen Zhu; Wen-Biao Ren; Xu Zhou; Long-Fei Liu; He-Qun Chen; Xiong-Bing Zu
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.